FDA grants priority review status for PaxVax’s Vaxchora single dose cholera vaccine
The agency has set 15 June 2016 as the action date for Vaxchora BLA. If approved, it would become the only anti-cholera vaccine in the US. PaxVax’s BLA
Voro Therapeutics and Alloy Therapeutics have formed a strategic research partnership to develop tumour-selective, next-generation masked T-cell engager (TCE) therapeutics.
MAT2501 is an orally-administered, encochleated formulation of the broad spectrum aminoglycoside antibiotic agent amikacin which may be used to treat different types of multidrug-resistant bacteria, including NTM and